YD Bio Limited Reports Full Year 2025 Financial Results
YD Bio Limited, a Nasdaq-listed biotechnology company, announced a 17% increase in net revenue for 2025 driven by pharmaceutical sales growth and product launches. Despite revenue gains, net loss widened due to increased operating expenses from research and development and business expansion. The company advanced its therapeutics and diagnostics pi…